Neovacs to present the preclinical results of its therapeutic vaccine candidate IL-4 / IL-13 Kinoid at Keystone Congress
March 21 2019 - 2:30AM
Neovacs to present the preclinical results of its therapeutic
vaccine candidate IL-4 / IL-13 Kinoid at Keystone Congress
PRESS RELEASE ·
PRESS RELEASE · PRESS
RELEASE
NEOVACS TO PRESENT THE PRECLINICAL
RESULTS OF ITS THERAPEUTIC VACCINE CANDIDATE IL-4
/ IL-13 KINOID AT KEYSTONE
CONGRESS:
“Origins of Allergic Disease: Microbial,
Epithelial and Immune Interactions”
TAHOE CITY (CA), USA – March 24 - 27,
2019
Paris and Boston, March 21, 2019
– 07h30am CET - Neovacs
(Euronext Growth Paris : ALNEV), a leader in
active immunotherapies for the treatment of autoimmune diseases,
today announced the presentation of the preclinical results of its
proof of concept in allergy with its new IL-4 / IL-13 Kinoid
therapeutic vaccine, during the poster session at the upcoming
Keystone allergy conference , taking place March 24 – 27,
2019, in Tahoe City, California,
United States.
This work conducted in collaboration with a
research team from the Institut Pasteur (Dr. Laurent Reber and Dr.
Pierre Bruhns), showed in a representative allergic asthma model
that a treatment with IL-4 / IL-13 Kinoid enhanced the production
of polyclonal antibodies which neutralized the two targeted
cytokines IL-4 and IL-13, both being development factors for
allergic asthma, thus avoiding the occurrence of any symptoms.
About
Keystone congress
Keystone Symposia will serve as a catalyst for
the advancement of biomedical and life sciences by connecting
scientists within and across disciplines at conferences and
workshops held at venues that create an environment conducive to
information exchange, generation of new ideas and acceleration of
applications that benefit society.
https://bit.ly/2JlEMwy
About Neovacs
Listed on Euronext Growth since 2010, Neovacs is
today a leading biotechnology company focused on an active
immunotherapy technology platform (Kinoids) with applications in
autoimmune and/or inflammatory diseases. On the basis of the
company’s proprietary technology for inducing a polyclonal immune
response (covered by four patent families that potentially run
until 2032) Neovacs is focusing its clinical development efforts on
IFNα-Kinoid, an immunotherapy being developed for the indication of
lupus, dermatomyositis and also in preclinical trial for Type 1
diabetes. Neovacs is also conducting preclinical development works
on other therapeutic vaccines in the fields of auto-immune
diseases, oncology and allergies. The goal of the Kinoid approach
is to enable patients to have access to safe treatments with
efficacy that is sustained in these life-long diseases.
www.neovacs.fr
Contacts
NEOVACS – Corporate Communication &
Investor RelationsCharlène Masson+33 1 53
10 93 00cmasson@neovacs.com
NEWCAP- Media
Annie-Florence Loyer +33 1 44 71 00 12 / + 33
6 88 20 35 59afloyer@newcap.fr Léa Jacquin +33 1
44 71 20 41 / +33 6 58 14 84 66ljacquin@newcap.fr
ORPHEON FINANCE – Financial
Communication and Investor RelationsJames
Palmer +33 7 60 92 77 74j.palmer@orpheonfinance.com
Neovacs (EU:ALNEV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Neovacs (EU:ALNEV)
Historical Stock Chart
From Jul 2023 to Jul 2024